StarTric

General Information

Company Name

StarTric

Founded Year

Location (Offices)

Italy +1

Founders / Decision Makers

Number of Employees

Industries

Manufacturing, Medical Devices

Funding Stage

Seed

Social Media

StarTric - Company Profile

StarTric is an Italian startup that is developing an innovative structural heart technology to treat the regurgitation of the tricuspid valve. The company's slogan "Transcatheter Tricuspid Valve Repair" highlights its focus. Founded by Prof. Ottavio Alfieri and Prof. Michele De Bonis, the company's transcatheter device aims to replicate the results of the Clover repair, a highly effective open surgery technique. With a focus on addressing tricuspid regurgitation, which affects a significant portion of the population, StarTric is positioned as a pioneer in next-generation technologies for tricuspid valve treatment. The company has received a Seed Round investment from Growth Engine and NLC in July 2024, indicating investor confidence in the startup's potential. Despite being still in development, StarTric's approach holds promise for addressing a critical cardiovascular condition and has the potential to make a substantial impact in the medical devices and manufacturing industries.

Taxonomy: structural heart technology, transcatheter tricuspid valve repair, minimally invasive device, cardiovascular disease treatment, transcatheter repair implantable device, professor-led innovation, tricuspid regurgitation, edge-to-edge repair technique, cardiac surgery, tricuspid valve, heart failure treatment, atrial fibrillation, medical device innovation, personalized healthcare, clinical device development